A Phase II/III, Randomized, Double-Masked, Vehicle-Controlled, Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers
Phase: PHASE2
Conditions: Healthy Volunteers
Sponsor: Sintetica SA

Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 1/42 
 
 
Medical University Vienna 
Allgemeines Krankenhaus 
Währinger Gürtel 18-20 
A-1090 Vienna 
Austria 
Phone: + 43 1 40400 29810 
Fax: + 43 1 40400 29980 
E-mail: Klin-Pharmakologie@meduniwien.ac.at 
http://www.meduniwien.ac.at/klpharm 
 
 
Study protocol 
  
A Phase II/III, Randomized, Double-Masked, Vehicle-Controlled, Efficacy, 
Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy 
Volunteers 
 
 
Protocol No: CHL.3-02-2019 
EudraCT No: 2020-000465-17 
 
 
Version 2.0, 04-May-2020 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 2/42 
Sponsor (AMG §§ 2a, 31, 32): 
Sintetica S.A. 
Via Penate 5, 
6850 Mendrisio, Switzerland 
Tel. +41 (0)91 640 42 50 
Fax +41 (0)91 646 85 61 
 
Sponsor’s Representative: 
Elisabetta Donati, PharmD, Corporate Director Scientific Affairs 
Email: edonati@sintetica.com 
 
 
Principal investigator (AMG §§ 2a, 35, 36):  
Assoc. Prof. Priv. Doz. Dr. Gerhard Garhöfer 
Department of Clinical Pharmacology 
Währinger Gürtel 18-20 
1090 Vienna 
Austria 
Tel: +43 1 40400 29810 
Fax: +43 1 40400 29900 
 
Clinical trial center: 
Department of Clinical Pharmacology 
Währinger Gürtel 18-20 
1090 Vienna 
Austria 
Phone: +43 1 40400 29810 
Fax:     +43 1 40400 29900 
 
CRO (AMG §§ 2a,33, 34): 
Iris Pharma 
Les Nertières 
Allée Hector Pintus 
06610 La Gaude 
France 
 
 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 3/42 
INVESTIGATOR SIGNATURE PAGE 
 
A Phase II/III, Randomized, Double-Masked, Vehicle-Controlled, Efficacy, Safety and Tolerability 
Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers 
 
I confirm that I have read and understood the protocol. I agree to meet all the obligations and 
restrictions outlined for me in the protocol. I will obtain written informed consent from all study 
participants prior to conducting any study procedures. All information regarding this protocol and the 
IMP will be treated as strictly confidential. I will conduct the study in all respects in accordance with 
the study protocol and the ethical principles of the current version of the declaration of Helsinki and 
GCP. 
 
SPONSOR: Sintetica S.A. 
 
Sponsor´s representative 
 
04.05.2020  
_______________ 
___________________________ 
Date 
 
 
signature 
 
 
 
INVESTIGATOR CENTER 
 
Principal Investigator: 
Assoc. Prof. Priv. Doz. Dr. Gerhard Garhöfer 
 
 
 
_______________ 
___________________________ 
date 
 
 
signature 
 
 
  
 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 4/42 
Study Synopsis 
 
Title 
A Phase II/III, Randomized, Double-Masked, Vehicle-Controlled, Efficacy, Safety 
and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers 
Study phase 
Phase II/III 
Principal investigator 
Assoc. Prof. Priv. Doz. Dr. Gerhard Garhöfer, Universitätsklinik für Klinische 
Pharmakologie, Allgemeines Krankenhaus Wien, Währinger Gürtel 18-20, A-1090 
Wien, Tel: +43 1 40400 29810 
Co-investigators 
Assoc. Prof. PD Dr. Doreen Schmidl, Dr. Nikolaus Hommer, Dr. Martin Kallab, Dr. 
Andreas Schlatter, Universitätsklinik für Klinische Pharmakologie, Allgemeines 
Krankenhaus Wien, Währinger Gürtel 18-20, A-1090 Wien; Tel. 40400-29810 
Data management  
Biostatistics 
IDDI, 30 av Provinciale, 1340, Louvain-la-Neuve, Belgium 
Agilis, Patriarchou loakim 1 and Pireos 209, 177 78 Tavros, Greece 
Background and aim 
Safe and efficient topical anaesthesia is crucial for surgical procedures in 
ophthalmology, such as cataract surgery. Usually, eye drops based on 
oxybuprocaine, lidocaine or tetracaine as pharmacologically active agents are 
used to provide local anaesthesia of the eye. 
Chloroprocaine is a local anaesthetic that is indicated for the production of local 
anaesthesia by infiltration, peripheral nerve block and central blocks, including 
spinal and epidural blocks. One of its key advantages is the fast metabolism by 
ester hydrolysis leading to a very short plasma half-life of less than 30 seconds. 
Therefore, also high concentrations can be used with large volumes and minimal 
risk of toxicity. As such, chloroprocaine is the ideal anaesthetic for regional 
anaesthesia in patients undergoing short-duration surgeries, providing rapid onset 
of action, adequate potency, predictable duration, fast recovery, and a safe 
toxicological profile when compared with other local anaesthetics.  
In the present study, a Chloroprocaine 3% Gel formulation for topical anaesthesia 
of the eye will be evaluated in healthy subjects. In addition to the above-mentioned 
benefits, the gel formulation has several other advantages. Most importantly, it 
tends to stay on the eye for a longer duration than commonly used eye drops due 
to its viscosity and is not drained by the punctae as quickly as drops with low 
viscosity. Due to its high viscous formulation, systemic absorption through the 
nasolacrimal system is expected to be low, therefore reducing the potential for 
systemic toxicity.  
The study will be carried out in 2 parts. In part I, safety and tolerability will be 
assessed in three groups (12 subjects per group) for single and multiple instillations 
(1 drop, 3 drops and 3+3 drops). In each group, 9 subjects will be randomized to 
receive Chloroprocaine 3% Gel and 3 subjects will receive vehicle as control in the 
right eye. After part I is completed, an internal independent board will review safety 
endpoints of data collected from these first subjects and advise to go on with further 
enrollment. 
If no safety concerns arise, in part II efficacy, safety and tolerability will be assessed 
in 60 healthy subjects for the 3 drops dose regimen. 40 subjects will receive 
Chloroprocaine 3% Gel and 20 will receive vehicle (2:1 randomization) in the right 
eye. 
Study objectives 
Primary objective: To assess efficacy of Chloroprocaine 3% ophthalmic gel in 
healthy volunteers 
Secondary objectives: To assess safety and tolerability of Chloroprocaine 3% 
ophthalmic gel in healthy volunteers 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 5/42 
Primary endpoint 
Estimate the proportion of subjects experiencing full anaesthesia of the ocular 
surface 5 minutes after administration of Chloroprocaine 3% ophthalmic gel 
Primary Hypothesis 
Administration of Chloroprocaine 3% ophthalmic gel leads to topical anesthesia 
within 5 minutes in healthy subjects 
Secondary endpoints: 
• 
Estimate time to anesthesia and duration of anesthesia, as well as Cochet 
Bonnet assessments 
• 
Assess the occurrence of: 
- Ocular symptoms 
- Adverse events  
• 
Blood pressure and heart rate 
• 
Slit lamp examination 
• 
Corneal fluorescein staining 
• 
Intraocular pressure 
Study design 
Randomized, Double-Masked, Vehicle-Controlled, Single-Center Study 
Study population 
A total of 96 healthy male and female subjects will be included in the study. The 
study will be performed in 2 parts. 
Part I: 
Group 1 (12 subjects): Single instillation 
Group 2 (12 subjects): 3 drops 
Group 3 (12 subjects): 3+3 drops 
In each group, 9 subjects will be randomized to receive Chloroprocaine 3% 
ophthalmic gel and 3 subjects will receive vehicle in the right eye. On the first two 
study days of each group, one subject will be dosed per day. On the third study 
day up to two subjects can be dosed per day. On the following study day(s) up to 
4 subjects can be dosed per day. Randomization will be performed in three blocks 
(3:1, Chloroprocaine vs. vehicle) for each group. After part I is completed, an 
internal independent board will review safety endpoints of data collected from these 
first subjects and advise to go on with further enrollment. 
Part II: 
60 subjects will be included in Part II. 40 subjects will be randomized to receive 3 
drops of Chloroprocaine 3% ophthalmic gel and 20 subjects will receive vehicle in 
the right eye (2:1 randomization, Chloroprocaine vs. vehicle). 
Investigational medicinal 
product (IMP) 
Chloroprocaine 3% ophthalmic Gel 
IMP 
Chloroprocaine 3% ocular gel,  
Sintetica S.A., Switzerland  
Manufacturer 
Unither Pharmaceuticals, France 
Pharmaceutical form 
Gel  
Dose 
Frequency 
1 drop 
1, 3 and 3+3 times 
Administration route 
Topical instillation 
Control 
Vehicle for Chloroprocaine 3% ophthalmic Gel 
IMP 
Placebo, Vehicle for chloroprocaine 3%  
ocular gel, Sintetica S.A., Switzerland 
Manufacturer 
Unither Pharmaceuticals, France 
Pharmaceutical form 
Gel  
Dose 
Frequency 
1 drop 
1, 3 and 3+3 times 
Administration route 
Topical instillation 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 6/42 
Topically administered 
medication for 
measurements 
Fluoresceine-Oxybuprocaine SDU Faure (Omnivision, Neuhausen), dose: 1 drop 
per eye for measurement of intraocular pressure 
Minims-Fluorescein Sodium 2.0% (Chauvin Pharmaceuticals Ltd. UK); dose: 1 
drop per eye for assessment of corneal staining 
Study procedures 
• 
Blood pressure and heart rate (automatic oscillometric device) 
• 
Ocular symptoms (100 mm visual analogue scale for burning, stinging, 
itching, foreign body sensation) 
• 
Far best corrected visual acuity using standard ETDRS charts 
• 
Slit lamp examination (eyelid swelling, eyelid redness, conjunctival 
chemosis, conjunctival hyperemia, cornea, anterior chamber flare) 
• 
Corneal fluorescein staining (according to the NEI scale) 
• 
Intraocular pressure (Goldmann applanation tonometry) 
• 
Funduscopy at the slit lamp  
• 
Pinching of the conjunctiva (0.3 mm forceps) 
• 
Cochet bonnet assessment of corneal sensitivity  
• 
Urine pregnancy test  
Inclusion criteria 
1. Signed and dated informed consent 
2. Healthy male or female aged from 18 to 90 years 
3. No clinically significant ocular or systemic disease 
4. Ability to orally respond to pain 
5. Ability to follow the visit schedule 
Exclusion criteria 
Ophthalmic exclusion criteria 
1. Eye movement disorder (i.e. Nystagmus) 
2. Dacryocystitis and all other pathologies of tears drainage system 
3. History of Inflammatory ocular disease (Iritis, uveitis, herpetic keratitis) 
4. Corneal, epithelial, stromal or endothelial, residual or evolutionary disease 
(including corneal ulceration and superficial punctuate keratitis) 
5. History of ocular traumatism, infection or inflammation within the last 3 
months 
6. Best corrected visual acuity < 1/10 
7. History of ophthalmic surgical complication (i.e. cystoid macular oedema) 
Systemic/non ophthalmic exclusion criteria  
8. General history: 
8.1 Deafness 
8.2 Excessive anxiety 
9. Any other medical or surgical history, disorder or disease such as acute or 
chronic severe organic disease: hepatic, endocrine neoplastic, 
haematological diseases, severe psychiatric illness, relevant 
cardiovascular abnormalities (such as unstable angina, uncontrolled 
hypertension: systolic blood pressure over 200 mm Hg, diastolic blood 
pressure over 100 mm Hg) and/or any complicating factor or structural 
abnormality judged by the investigator to be incompatible with the study 
10. Allergic history: Known hypersensitivity to one of the components of the 
study medications or to test products 
Specific non-inclusion criteria for women: 
11. Pregnancy, lactation 
12. Women without an effective method of contraception (i.e. oral 
contraceptive, intra-uterine device, subcutaneous contraceptive implant) 
OR 
13. Women not hysterectomised, not menopausal nor surgically sterilized 
Exclusion criteria related to general conditions: 
14. Inability of subject to understand the study procedures and thus inability to 
give informed consent 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 7/42 
15. Non-compliant subject (e.g. not willing to attend the follow-up visits, way 
of life interfering with compliance) 
16. Participation in another clinical study 
17. Already included once in this study 
18. Ward of court 
19. Subject not covered by the Social Security 
Exclusion criteria related to previous and concomitant medications (taken 
within 15 days prior screening visit) 
20. Use of systemic opioids and opioid drugs 
21. Topical ocular treatment with anaesthetic action 
22. Use of systemic analgesic drugs (except paracetamol, which will be 
allowed after Visit 2) 
Planned Duration of the 
study 
Approximately 6 months (first subject first visit to last subject last visit) 
Benefit/risk assessment 
Although there is no direct benefit for the subjects under study, the findings of this 
study may help to assess safety, tolerability and efficacy of ophthalmic 
Chloroprocaine 3% Gel. 
Chloroprocaine has been used for spinal, epidural and perineural anaesthesia for 
several years and is well tolerated. However, no data for the use in the human eye 
is currently available. Chloroprocaine 3% ophthalmic Gel is intended to be used for 
topical anaesthesia for patients undergoing eye surgery in the future. Due to its 
viscosity the gel tends to stay on the eye for a longer duration than eye drops and 
is not absorbed by the punctae as quickly as the tears and systemic absorption 
through the nasolacrimal system should be reduced, therefore reducing the 
potential for systemic toxicity.  
Data from the non-clinical development program reports good local tolerability of 
Chloroprocaine 3% ophthalmic gel on the ocular surface. Further, non-clinical data 
from a proof-of-concept study indicates a strong and long-lasting anaesthetic effect 
of Chloroporcaine 3% ophthalmic gel.  
However, at this stage of development, local toxicity of Chloroprocaine 3% Gel in 
human eyes cannot be ruled out but the risk is considered low based on the safety 
factor calculated using preclinical data. Considering the expected low systemic 
exposure, systemic side effects are unlikely to occur. The most common systemic 
side effect that was observed after intrathecal injection was systemic hypertonia. 
Although it is unlikely to occur after ophthalmic use, blood pressure and heart rate 
will be assessed after administration in the present study. 
Therefore, the risk/benefit ratio is acceptable. 
Statistical analysis 
Part I:  
In this part of the study, no formal statistical analysis (i.e. hypothesis testing) will 
take place. Safety will be assessed using the frequency of adverse events and 
results from the slit lamp evaluation. The safety board will decide whether the 
safety profile is acceptable to proceed in part II of the study.  
Part II: 
All parameters measured will be evaluated and presented using descriptive 
statistics, i.e. arithmetic mean, SD, minimum, median and maximum values for 
quantitative variables, and absolute and relative (%) frequencies for qualitative 
variables. In this part of the study, the list of quantitative variables includes time to 
anesthesia, duration of anesthesia, Cochet Bonnet assessment, blood pressure, 
heart rate, intraocular pressure, ocular symptoms, slit lamp examination and 
corneal fluorescein staining, while qualitative variables include the experience of 
full anesthesia of the ocular surface and the occurrence of adverse events. 
Moreover, results will be reported by treatment group. In terms of figures, 
quantitative variables will be presented by either histograms or box-plots, and 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 8/42 
qualitative variables will be presented by either bar-charts or pie-charts. 
Confidence intervals will be reported, where appropriate. If not stated elsewhere, 
these intervals will be two sided in each case and provide 95% confidence.  
The primary endpoint of the part II of the study is defined as the proportion of 
subjects gaining full anesthesia of the ocular surface 5 minutes after administration 
of the IMP for the 2 treatment arms (i.e. p1 for vehicle and p2 for Chloroprocaine 
arm). The null hypothesis of equal response rates between the 2 treatment arms 
(i.e. H0: p1=p2) at the α=0.05 level will be rejected if: 
ተተ
𝑝𝑝1
ෞ−𝑝𝑝2
ෞ
ට𝑝𝑝1
ෞ(1 −𝑝𝑝1
ෞ)
𝑛𝑛1
+ 𝑝𝑝2
ෞ(1 −𝑝𝑝2
ෞ)
𝑛𝑛2
ተተ> 𝑍𝑍𝛼𝛼/2 
 
In terms of statistical inference for the secondary endpoints, quantitative variables 
will be compared between the 2 groups using Mann-Whitney’s test, in which the 
null hypothesis is that for each quantitative variable tested, its median value does 
not differ significantly between the 2 groups (i.e. H0: median1=median2). Qualitative 
variables will be compared using Pearson’s X2 test, in which the null hypothesis for 
each pair of qualitative variables is that these two variables are not associated. To 
account for multiple comparisons, we will adjust the statistical significance level 
using Bonferroni corrections. 
In terms of adverse events, all AEs and SAEs will be reported in tabular form overall 
and separately for each treatment. Not available data will be evaluated as “missing 
values”. A statistical analysis plan (SAP) will be provided before database closure. 
A p-value<0.05 will be considered statistically significant. The statistical analysis 
will be performed using RStudio v. 1.2.5033 and/or IBM SPSS Statistics v. 25 (or 
newer) for Windows. 
 
 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 9/42 
Table of Contents 
1. Introduction ..................................................................................................................... 12 
1.1 
Background .................................................................................................................. 12 
1.2 
Rationale of the study ............................................................................................... 13 
1.3 
Benefit/risk assessment ........................................................................................... 14 
2. Study objectives ............................................................................................................... 15 
3. Investigational plan......................................................................................................... 15 
3.1 
Design ............................................................................................................................ 15 
3.2 
Selection of study population ................................................................................. 15 
3.2.1 
Number of subjects ................................................................................................................ 15 
3.2.2 
Inclusion criteria ..................................................................................................................... 16 
3.2.3 
Exclusion criteria .................................................................................................................... 16 
3.3 
Medication .................................................................................................................... 17 
3.3.1 
Investigational Medicinal Product (IMP) ............................................................................. 17 
3.3.2 
IMP handling and accountability .......................................................................................... 18 
3.3.2.1 
Handling and Storage ...................................................................................................... 18 
3.3.2.2 
Packaging and labelling .................................................................................................. 18 
3.3.2.3 
Administration ................................................................................................................ 18 
3.3.2.4 
Accountability ................................................................................................................. 18 
3.3.3 
Topical medication for investigations .................................................................................. 19 
3.3.4 
Randomization and masking ................................................................................................ 19 
3.4 
Study procedures ....................................................................................................... 20 
3.4.1 
Prestudy Screening ............................................................................................................... 20 
3.4.2 
Description of the study days ............................................................................................... 20 
3.4.3 
Withdrawal and replacement of subjects ........................................................................... 22 
3.4.4 
Study stopping rules .............................................................................................................. 23 
3.4.5 
Protocol deviations ................................................................................................................ 23 
3.4.5.1  
Withdrawal criteria ......................................................................................................... 23 
3.4.5.2  
Discontinuation procedures ............................................................................................ 24 
3.5 
Variables and schedule of observations .............................................................. 24 
3.5.1 
Outcome variables ................................................................................................................. 24 
3.6 
Equipment used for assessing the clinical investigation variables ............. 24 
4. Methods of evaluation ..................................................................................................... 25 
4.1 
Measurement techniques ......................................................................................... 25 
4.1.1 
Noninvasive measurement of systemic hemodynamics .................................................. 25 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 10/42 
4.1.2 
Ocular symptoms ................................................................................................................... 25 
4.1.3 
Far best corrected visual acuity ........................................................................................... 25 
4.1.4 
Slit lamp examination ............................................................................................................ 25 
4.1.5 
Corneal fluorescein staining ................................................................................................. 25 
4.1.6 
Intraocular pressure .............................................................................................................. 25 
4.1.7 
Funduscopy ............................................................................................................................ 25 
4.1.8 
Assessment of conjunctival anaesthesia ........................................................................... 25 
4.1.9 
Cochet-Bonnet assessment ................................................................................................. 26 
4.1.10 
Urine Pregnancy test ........................................................................................................ 26 
4.2 
Adverse events ........................................................................................................... 26 
4.2.1 
Adverse events recorded throughout the study ................................................................ 26 
4.2.2 
Definitions ............................................................................................................................... 27 
4.2.3 
AEs monitoring window......................................................................................................... 28 
4.2.4 
AEs recording ......................................................................................................................... 28 
4.2.5 
SAEs reporting ....................................................................................................................... 30 
4.2.6 
SUSARs management .......................................................................................................... 30 
4.2.7 
Other events qualified for expedited reporting .................................................................. 31 
4.2.8 
SAEs: contacts ....................................................................................................................... 31 
4.3 
Data handling procedures ........................................................................................ 31 
4.4 
Statistical methods .................................................................................................... 32 
4.4.1 
Determination of sample size ............................................................................................... 32 
4.4.2 
Analysis sets ........................................................................................................................... 32 
4.4.3 
Handling of missing data ...................................................................................................... 33 
4.4.4 
Statistical analysis plan ......................................................................................................... 33 
5. Ethical and legal aspects................................................................................................. 35 
5.1 
Informed consent of subjects ................................................................................. 35 
5.2 
Approval of the study/Protocol Amendment/Study Termination .................. 35 
5.2.1 
Approval of the study ............................................................................................................ 35 
5.2.2 
Protocol Amendment ............................................................................................................. 35 
5.2.3 
Study Termination .................................................................................................................. 35 
5.3 
Insurance ...................................................................................................................... 36 
5.4 
Confidentiality ............................................................................................................. 36 
5.5  
Patients compensation ............................................................................................. 36 
5.6  
Study Duration ............................................................................................................ 36 
6. Data quality assurance.................................................................................................... 36 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 11/42 
6.1 
Monitoring .................................................................................................................... 36 
6.2 
Documentation of study findings ........................................................................... 37 
6.3 
Auditing and inspections ......................................................................................... 37 
7. Publication policy ............................................................................................................ 37 
8. References ....................................................................................................................... 38 
9. Appendix: Schedule of assessments ............................................................................... 39 
 
  

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 12/42 
1. Introduction 
1.1 
Background 
Safe and efficient topical local anaesthesia is crucial for surgical procedures in ophthalmology, such 
as cataract surgery, intravitreal injections, refractive surgery or others. The development of less 
invasive surgical techniques, which allow for most interventions to be performed as outpatient 
surgeries, has stimulated the development of new approaches in topical aesthesia. Currently, 
oxybuprocaine, lidocaine or tretracaine as pharmacologically active agents - mostly formulated as 
liquid eye drops - are used to provide local anesthesia of the eye.1 However, it has been hypothesized 
that formulations with optimized physical and chemical properties such as high viscosity gel based 
formulations might be superior to eye drops in terms of efficacy and safety.  
Background on Chloroprocaine 
Chloroprocaine is a local anaesthetic that has been widely used for spinal, epidural and perineural 
anaesthesia.2 Chloroprocaine, like other local anesthetics in this group, reduces signal conduction in 
neurons by altering the Na+ channels in the neuronal cell membrane responsible for the action 
potential propagation. Pharmacologically speaking, one of the key advantages of Chloroprocaine is 
the fast onset (usually within minutes) and the fast metabolization by ester hydrolysis, which leads 
to a very short plasma half-life of less than 30 seconds. This leads to good controllability and also 
high concentrations can be used with minimal risk of toxicity. As such, Chloroprocaine is the ideal 
anesthetic for regional anesthesia in patients undergoing short-duration surgeries, providing rapid 
onset of action, adequate potency, predictable duration, fast recovery, and a safe toxicological profile 
when compared to other local anesthetics. 
The current study aims to investigate the efficacy, safety and tolerability of a newly developed 
Chloroprocaine ophthalmic gel in humans. Based on theoretical considerations, one can hypothesize 
that a gel formulation could provide additional benefits compared to a drop solution. First, because 
of its high viscosity, gel formulations stay longer on the ocular surface and may therefore provide a 
longer anesthetic effect. Secondly, because of the gel nature of the formulation, the drainage of the 
drug through the nasolacrimal drainage system is reduced, which might limit absorption through the 
nasal mucosa and thus lead a low systemic exposure of the drug. 
Regulatory status of Chloroprocaine  
Chloroprocaine is marketed since 1955 in the USA and Canada for epidural aesthesia and peripheral 
blocks (Nesacaine® 1%, 2%, 3% injection). In the European Community, Chloroprocaine has 
received market authorization (Ampres® 10mg/ml Injektionslösung) for spinal anesthesia in adults 
where the planned surgical procedure should not exceed 40 minutes. An extension application for 
the existing marketing authorization (new strength of 20mg/ml, new route of administration: 
perineural anesthesia) is currently under review. 
Non-clinical development 
As Chloroprocaine is widely used for different routes of administration, the toxicological profile is well 
described.  

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 13/42 
Animal studies report a good safety profile and did not report any particular sign of systemic toxicity 
beside those already known for this class of local anesthetics. For more details on systemic 
toxicology please refer to the investigator’s brochure. 
Non-clinical safety and Toxicology on the eye 
Local tolerability and safety and proof-of-concept of Chloroprocaine 3% eye drops has been 
investigated in a non-clinical development program. Data of a GLP ocular irritation study in rabbits 
reports good tolerability of the formation on the ocular surface (Study Number 14-01765-G2, Study 
on File). Further, a 7-day GLP local tolerance study including histopathological assessments in 
rabbits confirms good tolerance on the ocular surface. (Study number: S104CH20118, Study on file). 
A non-GLP efficacy study performed in a rabbit animal model supports the concept of Chloroprocaine 
3% ophthalmic gel (Study A66C06315, S104CH20318, Studies on file), showing an anesthetic 
potency up to 60 minutes after instillation depending on the viscosity of the gel formulation. An in-
depth description of the non-clinical development program is given in the investigator´s brochure. 
 
1.2 
Rationale of the study 
Scientific advice on the planned clinical development plan has been obtained from the FDA in Sept. 
2019. As part of this development plan and following the advice from the competent authority a 
combined phase II/III study will be performed as described here in this study protocol.  
In the present study, the efficacy, safety and tolerability of Chloroprocaine 3% ophthalmic gel for 
topical anaesthesia of the eye will be evaluated in healthy subjects. Based on theoretical 
assumptions it is reasonable to expect that the formulation under study offers significant advantages 
compared to currently available formulations. Most importantly, because of its gel nature it stays 
longer on the ocular surface than commonly used eye drops due to its viscosity and is not drained 
by the punctae as quickly as drops with low viscosity.3 Due to its high viscous formulation, systemic 
absorption through the nasolacrimal system is expected to be low, therefore reducing the potential 
for systemic toxicity. 
The study will be carried out in 2 parts. In part I, safety and tolerability will be assessed in three 
groups (12 subjects per group) for single and multiple instillations (1 drop, 3 drops and 3+3 drops). 
In each group, 9 subjects will be randomized to receive Chloroprocaine 3% Gel and 3 subjects will 
receive vehicle as control in the right eye. After part I is completed, an internal independent board 
will review safety endpoints of data collected from these first subjects and advise to go on with further 
enrollment. 
If no safety concerns arise, in part II efficacy, safety and tolerability will be assessed in 60 healthy 
subjects for the 3 drops dose regimen. 40 subjects will receive Chloroprocaine 3% Gel and 20 will 
receive vehicle (2:1 randomization) in the right eye. 
Dosage rationale 
The selected dose of Chloroprocaine gel is derived from animal data. In an ocular tolerance study 
(Study Number: S104CH20118) in New Zealand White Rabbits a 5 day 5 times daily administration 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 14/42 
of Chloroprocaine ophthalmic gel was well tolerated. A transient absence of pupillary reflex and 
partial mydriasis were observed for eyes treated with Chloroprocaine gel 3% after each last daily 
administration. In summary, five daily instillations over 5 days of Chloroprocaine gel 3% in the right 
eyes of albino rabbits were both macroscopically and microscopically well tolerated. 
A non-clinical dose finding study investigating Chloroprocaine 5% gel, Chloroprocaine 3% high 
viscosity gel and Chloroprocaine 3% low viscosity gel was performed in New Zealand White rabbits 
(Study number: A66C06315). Whereas Chloroprocaine 5% gel showed only limited tolerability on the 
ocular surface and was therefore not further continued, Chloroprocaine 3% showed good tolerability 
together with a long anesthetic potential (up to 60 minutes for the high viscosity gel, up to 45 minutes 
for the low viscosity gel). Based on this data, Chloroprocaine 3% high viscosity gel was chosen for 
further development. The performance of the selected formulation (Chloroprocaine 3% high viscosity 
gel, batch number 1708L08) was then confirmed in a further study in group of 6 albino rabbits (Study 
Number: S104CH20318), again showing a good anesthetic potential of Choroprocaine 3% gel. 
 
1.3 
Benefit/risk assessment 
Although there is no direct benefit for the subjects under study, the findings of this study may help to 
assess safety, tolerability and efficacy of ophthalmic Chloroprocaine 3% Gel. 
Chloroprocaine has been used for spinal, epidural and perineural anaesthesia for several years and 
is well tolerated. In particular, chloroprocaine solutions (i.e. Nesacaine® 1, 2, 3%) have been 
marketed in USA and Canada since 1955. Until now, no data for the use in the human eye is currently 
available. However, the local and systemic efficacy and safety of chloroprocaine is well-known from 
other routes of administration. Chloroprocaine 3% ophthalmic Gel is intended to be used for topical 
anaesthesia for patients undergoing eye surgery in the future. Due to its viscosity the gel tends to 
stay on the eye for a longer duration than eye drops is not absorbed by the punctae as quickly as 
the tears and systemic absorption through the nasolacrimal system should be reduced, therefore 
reducing the potential for systemic toxicity.  
Data from the non-clinical development program reports good local tolerability of Chloroprocaine 3% 
ophthalmic gel on the ocular surface. Further, non-clinical data from a proof-of-concept study 
indicates a strong and long-lasting anesthetic effect of Chloroprocaine 3% ophthalmic gel.  
However, at this stage of development, local toxicity of Chloroprocaine 3% Gel in human eyes cannot 
be ruled out but the risk is considered low based on the safety factor calculated using preclinical 
data. Considering the expected low systemic exposure, systemic side effects are unlikely to occur. 
The most common systemic side effect that was observed after intrathecal injection was systemic 
hypertonia. Although it is unlikely to occur after ophthalmic use, blood pressure and heart rate will be 
assessed after administration in the present study. 
Therefore, the risk/benefit ratio is acceptable. 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 15/42 
 
2. Study objectives  
Primary objective 
• 
To assess efficacy of Chloroprocaine 3% ophthalmic gel in healthy subjects 
Secondary objective 
• 
To assess safety and local tolerability of Chloroprocaine 3% ophthalmic gel 
Primary endpoint 
• 
Proportion of subjects gaining full anesthesia of the ocular surface 5 minutes after 
administration of Chloroprocaine 3% ophthalmic gel 
Secondary Endpoints 
• 
Safety and tolerability as assessed by the occurrence of ocular symptoms, adverse event 
occurrence and concomitant medication 
• 
Time of anesthesia and duration of anesthesia, as well as Cochet Bonnet assessments 
• 
Blood pressure and heart rate 
• 
Slit lamp examination 
• 
Corneal fluorescein staining 
• 
Intraocular pressure 
 
3. Investigational plan 
3.1 
Design 
Randomized, Double-Masked, Vehicle-Controlled, Single-Center Study 
3.2 
Selection of study population 
The participants will be recruited from the database of the Department of Clinical Pharmacology, 
Währinger Gürtel 18-20, A-1090 Wien, Austria. 
3.2.1 Number of subjects 
A total of 96 healthy male and female subjects will be included in the study. The study will be 
performed in 2 parts. 
Part I: 
- 
Group 1 (12 subjects): Single instillation 
- 
Group 2 (12 subjects): 3 drops 
- 
Group 3 (12 subjects): 3+3 drops 
In each group, 9 subjects will be randomized to receive Chloroprocaine 3% Gel and 3 subjects will 
receive vehicle in the right eye. On the first two study days of each group, one subject will be dosed 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 16/42 
per day. On the third study day up to two subjects can be dosed per day. On the following study 
day(s) up to 4 subjects can be dosed per day. Randomization will be performed in three blocks (3:1, 
Chloroprocaine vs. vehicle) for each group. After part I is completed, an internal independent board 
will review safety endpoints of data collected from these first subjects and advise to go on with further 
enrollment. 
Part II: 
60 subjects will be included in Part II. 40 subjects will be randomized to receive 3 drops of 
Chloroprocaine 3% Gel and 20 subjects will receive vehicle in the right eye (2:1 randomization, 
Chloroprocaine vs. vehicle). 
3.2.2 Inclusion criteria 
1. Signed and dated informed consent 
2. Healthy male or female aged from 18 to 90 years 
3. No clinically significant ocular or systemic disease 
4. Ability to orally respond to pain 
5. Ability to follow the visit schedule 
3.2.3 Exclusion criteria 
Ophthalmic exclusion criteria 
1. Eye movement disorder (i.e. Nystagmus) 
2. Dacryocystitis and all other pathologies of tears drainage system 
3. History of Inflammatory ocular disease (Iritis, uveitis, herpetic keratitis) 
4. Corneal, epithelial, stromal or endothelial, residual or evolutionary disease (including corneal 
ulceration and superficial punctuate keratitis) 
5. History of ocular traumatism, infection or inflammation within the last 3 months 
6. Best corrected visual acuity < 1/10 
7. History of ophthalmic surgical complication (i.e. cystoid macular oedema) 
Systemic/non ophthalmic exclusion criteria  
8. General history: 
8.1 Deafness 
8.2 Excessive anxiety 
9. Any other medical or surgical history, disorder or disease such as acute or chronic severe 
organic disease: hepatic, endocrine neoplasic, haematological diseases, severe psychiatric 
illness, relevant cardiovascular abnormalities (such as unstable angina, uncontrolled 
hypertension: systolic blood pressure over 200 mmHg, diastolic blood pressure over 100 
mmHg) and/or any complicating factor or structural abnormality judged by the investigator to 
be incompatible with the study 
10. Allergic history: Known hypersensitivity to one of the components of the study medications 
or to test products 
 
Specific non-inclusion criteria for women: 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 17/42 
11. Pregnancy, lactation 
12. Women without an effective method of contraception (i.e. oral contraceptive, intra-uterine 
device, subcutaneous contraceptive implant) 
OR 
13. Women not hysterectomised, not menopaused nor surgically sterilized 
Exclusion criteria related to general conditions: 
14. Inability of subject to understand the study procedures and thus inability to give informed 
consent 
15. Non-compliant subject (e.g. not willing to attend the follow-up visits, way of life interfering 
with compliance) 
16. Participation in another clinical study 
17. Already included once in this study 
18. Ward of court 
19. Subject not covered by the Social Security 
Exclusion criteria related to previous and concomitant medications (taken within 15 days prior 
screening visit) 
20. Use of systemic opioids and opioid drugs 
21. Topical ocular treatment with anaesthetic action 
22. Use of systemic analgesic drugs (except paracetamol, which will be allowed after Visit 2) 
 
3.3 
Medication 
3.3.1 Investigational Medicinal Product (IMP) 
IMP: Chloroprocaine 3% Gel 
IMP 
Chloroprocaine 3% ocular gel, Sintetica S.A., Switzerland 
Manufacturer 
Unither Pharmaceuticals, France 
Pharmaceutical form 
Gel  
Dose 
Frequency 
1 drop 
1, 3 and 3+3 times 
Administration route 
Topical instillation 
Placebo: Vehicle for Chloroprocaine 3% Gel 
IMP 
Placebo, Vehicle for chloroprocaine 3% ocular gel, Sintetica 
S.A., Switzerland 
Manufacturer 
Unither Pharmaceuticals, France 
Pharmaceutical form 
Gel  
Dose 
Frequency 
1 drop 
1, 3 and 3+3 times 
Administration route 
Topical instillation 
 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 18/42 
Dose: 
Part I: 
• 
Group 1 (12 subjects): Single instillation 
• 
Group 2 (12 subjects): 3 drops (1 instillation every minute ± 15 seconds) 
• 
Group 3 (12 subjects): 3+3 drops (1 instillation every minute ± 15 seconds for the first 3 
drops, then wait for 5 minutes before new instillation every minute ± 15 seconds for the last 
3 drops) 
Part II: 
• 
3 drops (1 instillation every minute ± 15 seconds) 
3.3.2 IMP handling and accountability 
3.3.2.1 
Handling and Storage 
IMP and placebo will be stored at temperature between 15°C and 25°C and protected from direct 
light.  
The investigator, the hospital pharmacist or other personnel allowed to store and dispense the IMP 
will be responsible for ensuring that the IMP used in the clinical investigation is securely maintained 
and in accordance with the applicable regulatory requirements. 
3.3.2.2 
Packaging and labelling 
Packaging and labelling will be carried out by the Sponsor according to the randomization list.  
All labels will be written in the local language. The content of the labelling is in accordance with the 
GMP specifications, according to the Annex 13 to the Good Manufacturing Practice and local 
requirements. 
3.3.2.3 
Administration 
The IMP must be administered only to study subjects who have signed informed consent and in 
accordance with the protocol. A designated member of the study team (as set out in the delegation 
log) will be responsible for administration according to the randomization procedure. Only the right 
eye of each subject will be treated. 
3.3.2.4 
Accountability 
The test and reference investigational products will be provided directly to the investigator by the 
sponsor. 
After receipt of the investigational products supply, the pharmacist or the person identified as the 
recipient of the study drug supply will confirm receipt. 
Each unit must be accounted in a specific form according to ICH GCP recommendation. 
The investigational materials are to be handled by the investigator or by study team members at the 
site designated and are to be used in accordance with this protocol only. Under no circumstances 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 19/42 
will the investigator allow the investigational product to be used other than as directed by this 
protocol. 
The responsibilities of personnel designated to handle IMP will be specified in written prior to their 
undertaking responsibilities related to the handling of the IMP. 
At the end of the study, used, unused and partially used supplies of Investigational Medicinal 
Products provided by the sponsor will either be destroyed on site (upon written authorization) or 
returned to the sponsor/manufacturer (upon written authorization), after assessment of drug 
accountability. 
3.3.3 Topical medication for investigations 
Fluorescein/Oxybuprocaine SDU Faure® (Oxybuprocainhydrochlorid with fluorescein, Omnivision 
AG, Austria, Neuhausen); dose: 1 drop per eye for measurement of intraocular pressure 
Minims-Fluorescein Sodium 2,0% (Chauvin Pharmaceuticals Ltd. UK); dose: 1 drop per eye for 
assessment of corneal staining 
3.3.4 Randomization and masking 
A subject who has given informed consent and who is included will be assigned a specific 
randomization number on the first study day. Randomization numbers will be allocated in ascending 
order using the next available consecutive number. The randomization number should be recorded 
in the subject’s source document and the Case Report Form (CRF).  
For both study parts, treatment assignment will be implemented through an IRT (interactive response 
technology) system using an unstratified permutated block randomization. 
The study will be carried out in a double-masked fashion, therefore the investigators and study site 
staff as well as the study participants will not be informed about the treatment dispensed. Drug 
accountability will also be performed only by designated personnel who is not involved in the study 
related procedures.  
The study will be performed in 2 parts. 
Part I: 
• 
Group 1 (12 subjects): Single instillation 
• 
Group 2 (12 subjects): 3 drops (1 instillation every minute ±15 seconds) 
• 
Group 3 (12 subjects): 3+3 drops (1 instillation every minute ±15 seconds, 5 minutes 
between each 3 drops set) 
In each group, 9 subjects will be randomized to receive Chloroprocaine 3% Gel and 3 subjects will 
receive vehicle in the right eye. On the first two study days of each group, one subject will be dosed 
per day. On the third study day up to two subjects can be dosed per day. On the following study 
day(s) up to 4 subjects can be dosed per day. Randomization will be performed in three blocks (3:1, 
Chloroprocaine vs. vehicle) for each group. After part I is completed, an internal independent board 
will review safety endpoints of data collected from these first subjects and advise to go on with further 
enrollment. 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 20/42 
Part II: 
60 subjects will be included in Part II. 40 subjects will be randomized to receive 3 drops (1 instillation 
every minute ±15 seconds) of Chloroprocaine 3% Gel and 20 subjects will receive vehicle in the right 
eye (2:1 randomization, Chloroprocaine vs. vehicle). 
A randomized subject discontinued from the study without being treated will be replaced. This will be 
done according to the randomization list. Withdrawn subjects randomized and treated will not be 
replaced. 
 
3.4 
Study procedures 
3.4.1 Prestudy Screening 
Visit 1 (Day -30 to Day -7) 
Time frame: 1.5 hours 
The screening examination will be performed before the start of the experiments and is identical for 
Part I and Part II: 
• 
Informed consent 
• 
Pregnancy test in females of childbearing potential 
• 
Demography 
• 
Ocular medical and surgical history 
• 
Systemic medical and surgical history 
• 
Previous (last 15 days) and concomitant ocular and non-ocular treatments 
• 
Check of inclusion/exclusion criteria 
• 
Height and weight 
• 
Blood pressure and heart rate. 
• 
Ocular symptoms 
• 
Best far corrected visual acuity in both eyes 
• 
Slit lamp examination including corneal fluorescein staining in both eyes 
• 
Measurement of intraocular pressure (IOP) by Goldmann applanation tonometry in both 
eyes 
• 
Funduscopy in both eyes 
3.4.2 Description of the study days 
Visit 2 (Day 1) 
Part I: 
Time frame: 2,5 hours 
The following examinations will be carried out in the following order: 
• 
Adverse Events/concomitant medication 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 21/42 
• 
Pregnancy test in females of childbearing potential 
• 
Blood pressure and heart rate. 
• 
Assessment of ocular symptoms 
• 
Slit lamp examination (both eyes) 
• 
Recheck of inclusion/exclusion criteria 
• 
Randomization 
• 
Instillation of the study medication in the right eye 
• 
A break of at least 60 minutes ±10 minutes will be scheduled 
• 
Blood pressure and heart rate 
• 
Assessment of ocular symptoms 
• 
Slit lamp examination (both eyes) 
• 
Assessment of Adverse Events 
Part II: 
Time frame: 2,5 hours 
The following examinations will be carried out in the following order: 
• 
Adverse Events/concomitant medication 
• 
Pregnancy test in females of childbearing potential 
• 
Blood pressure and heart rate. 
• 
Assessment of ocular symptoms 
• 
Slit lamp examination (both eyes) 
• 
Recheck of inclusion/exclusion criteria 
• 
Randomization 
• 
Instillation of the study medication in the right eye 
• 
Assessment of conjunctival anaesthesia* (right eye only) 
• 
Cochet Bonnet assessment** (right eye only) 
• 
Assessment of ocular symptoms (at the end of the study day) 
• 
Blood pressure and heart rate (at the end of the study day) 
• 
Slit lamp examination (both eyes, at the end of the study day) 
• 
Assessment of Adverse Events (throughout the study day) 
*Subjects will be tested and then questioned about pain at 20 seconds, 40 seconds, and 1 minute 
and in cases where they do report pain at the 20 and 40 seconds time point but not at the 1 minute 
timepoint, additional testing will be performed at 80 seconds. The resting intervals will be extended 
to every 5 minutes once a subject reported no pain on two successive tests. These subjects will be 
considered to have achieved the primary endpoint of anesthesia by 5 minutes.  
Alternatively, if the subject experiences pain at 20, 40, and 60 seconds, pinching will be suspended 
to the 5-minute time point. If the subject experiences pain at this testing interval (5 minutes), no more 
testing will be performed and the subject will be considered not to have gained anesthesia. 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 22/42 
**Cochet Bonnet assessment will either be performed at the 1 minute or 80 seconds time point only. 
Thereafter, Cochet Bonnet assessment will always be performed immediately after conjunctival 
pinching. 
 
Visit 3 (Day 2) 
Time frame: 10 minutes 
A phone visit will be performed in Part I and II and subjects will be asked about: 
• 
Changes in concomitant medication 
• 
Adverse Events 
 
Visit 4 (Day 8 ± 1) 
Time frame: 1 hour 
The following examinations will be carried out (Part I and Part II): 
• 
Adverse Events/concomitant medication 
• 
Blood pressure and heart rate 
• 
Assessment of ocular symptoms 
• 
Best far corrected visual acuity in both eyes 
• 
Slit lamp examination including corneal fluorescein staining in both eyes 
• 
Measurement of intraocular pressure (IOP) in both eyes 
• 
Funduscopy in both eyes 
 
Visit 5 (Day 29 ± 3) 
Time frame: 10 minutes 
A phone visit will be performed in Part I and II and subjects will be asked about: 
• 
Changes in concomitant medication 
• 
Adverse Events 
 
3.4.3 Withdrawal and replacement of subjects 
Subjects must be withdrawn under the following circumstances: 
• 
at their own request, 
• 
if the investigator feels it would not be in the best interests of the subject to continue, 
• 
if the subject violates the conditions laid out in the consent form/information sheet or 
disregards instructions by the study personnel on purpose. 
In all cases, the reasons why subjects are withdrawn must be recorded in detail in the case report 
form and in the source data sheet. A final examination is to be done for each withdrawn subject. 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 23/42 
Only randomized subjects not treated will be replaced.  
 
3.4.4 Study stopping rules 
Any subject can withdraw its consent to participate in the study without any reason. A final 
examination should be performed to ensure safety of the patient. 
The study may be prematurely terminated for a subject if SAEs or other significant side effects occur 
or if any other medical or ethical reasons do not justify continuation of the study, according to 
Investigator judgement. 
At the end of part 1, the Independent Board will review safety data of the subjects included in part 1 
and advise to go on with further enrollment with part 2. 
The sponsor or the investigator has the right to close this study at any time. As far as possible, this 
should occur after mutual consultation. As required by the Clinical Trials legislation, the IEC/IRB/CA 
must be informed.  
Should the study be discontinued prematurely, all study materials (completed, partially completed 
and empty case record forms) will be retained. 
 
3.4.5 Protocol deviations 
The Investigator should not implement any deviation from the protocol without prior review and 
agreement by the Ethics Committee and the competent authorities, except when necessary to 
eliminate an immediate hazard to study subjects. Any deviation from the protocol will be documented 
in writing (note to file or protocol deviation) by the principal investigator. 
For purposes of this protocol, major protocol deviations are defined as: 
• 
Subject entered into the study even though he/she did not satisfy entry criteria 
• 
Subject who developed withdrawal criteria during the study and was not withdrawn 
In case of a major protocol deviation, subjects may be excluded from the analysis.  
3.4.5.1  Withdrawal criteria 
It will be documented whether or not each subject completed the clinical study. If, for a subject, study 
treatment or observations are discontinued, the type of discontinuation and the primary reason for 
discontinuation will be recorded. 
Patients who will present any kind of complications preventing primary endpoint assessment to be 
performed, will be withdrawn from the efficacy analysis. However, these patients will be followed for 
safety parameters assessments. 
Moreover, if, in the opinion of the investigator, there is any other situation or condition which puts the 
subject at significant risk, patients should be withdrawn from the study too. 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 24/42 
Any patient may voluntarily discontinue the study at any time he or she chooses (Declaration of 
Helsinki), without prejudice. The investigator may elect to discontinue a patient for reasons related 
to the study product (e.g., AE). Such details should be recorded on the patient source data and CRF 
and reported separately. A final examination is to be done for each withdrawn subject. 
3.4.5.2  Discontinuation procedures 
For any subject discontinuing from interventions and findings, the investigator will:  
• 
ask the subject to undergo, as far as possible, a final medical visit to examine the subject's health 
conditions  
• 
arrange for alternative medical care of the withdrawn subject, if necessary 
• 
report in the source data and CRF date and time of the investigational product administration, 
and date and primary reason of study discontinuation 
• 
record in the source data and CRF any follow-up, if the subject is withdrawn for an AE 
Discontinued subjects will not be replaced. 
 
3.5 
Variables and schedule of observations 
3.5.1 Outcome variables 
Primary endpoint: 
• 
Efficacy of Chloroprocaine 3% gel eye drops, which is defined as the proportion of 
subjects gaining full anesthesia of the ocular surface 5 minutes after administration of 
the IMP 
Secondary endpoints: 
• 
Assess the time to anesthesia and duration of anesthesia, as well as Cochet Bonnet 
assessments 
• 
Assess the occurrence of: 
o 
Ocular symptoms 
o 
Adverse event occurrence 
• 
Blood pressure and heart rate 
• 
Slit lamp examination 
• 
Corneal fluorescein staining 
• 
Intraocular pressure 
 
3.6 
Equipment used for assessing the clinical investigation variables 
All used equipment should be monitored and calibrated if necessary and maintained according to 
the instructions of use. 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 25/42 
 
4. Methods of evaluation 
4.1 
Measurement techniques 
4.1.1 Noninvasive measurement of systemic hemodynamics 
Systolic, diastolic and mean blood pressures (SBP, DBP, MAP) are measured on the upper arm by 
an automated oscillometric device. Pulse rate is automatically recorded from a finger pulse-
oxymetric device. 
4.1.2 Ocular symptoms 
Scores will be determined using a 100 mm VAS on which 0 means “no symptoms” and 100 means 
“worst possible discomfort”. The following symptoms will be assessed using VAS: burning, stinging, 
itching, foreign body sensation. 
4.1.3 Far best corrected visual acuity 
Far best-corrected visual acuity will be measured using the standard ETDRS acuity charts. 
4.1.4 Slit lamp examination 
Slit lamp biomicroscopy will be performed for the following parameters: Conjunctival redness, 
anterior chamber flare, conjunctival chemosis, eyelid swelling and will be graded on a 4 point scale: 
(0) none, (1) mild, (2) moderate, (3) severe. 
4.1.5 Corneal fluorescein staining 
Minims-Fluorescein Sodium 2.0% eye drops will be used to detect corneal epithelial defects using 
slit lamp biomicroscopy. As grading scale for corneal damage, the NEI/Industry Workshop guidelines 
will be used 4. The cornea will be divided into five sectors (central, superior, inferior, nasal and 
temporal), each of which is scored on a scale of 0–3, whereas 0 means no staining and 3 means 
maximum staining, with a maximal score of 15. 
4.1.6 Intraocular pressure 
Intraocular pressure will be measured with a slit-lamp mounted Goldmann applanation tonometer. 
Before each measurement one drop of oxybuprocainhydrochloride combined with sodium 
fluorescein will be used for local anesthesia of the cornea. 
4.1.7 Funduscopy 
Indirect ophthalmoscopy will be performed at the slit lamp using a +90 diopters Volk lens.5 
4.1.8 Assessment of conjunctival anaesthesia 
Conjunctival anaesthesia will be assessed by pinching of the conjunctiva with 0.3-mm forceps. 
Subjects will be tested every 20 seconds during the first minute following last instillation of the study 
product. Subjects will be asked to immediately report if they feel pain. 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 26/42 
The testing intervals will be extended to every 5 minutes once a subject reported no pain on two 
successive tests.  
Assessment will be done as follows: Subjects will be tested at 20 seconds, 40 seconds, 60 seconds 
and 80 seconds if needed (if a subject reports pain at 20 and 40 seconds, but no pain at 60 seconds, 
a forth test should be performed at 80 seconds). 
These subjects with no pain on two successive tests will be considered to have achieved the primary 
endpoint of anesthesia by 5 minutes. Testing will be then repeated every 5 minutes to assess 
duration of anaesthesia. 
Alternatively, if the subject experiences pain at 20, 40, and 60 seconds, pinching will be suspended 
to the 5-minute time point. If the subject experiences pain at this testing interval (5 minutes), no 
more testing will be performed and the subject will be considered not to have gained anesthesia.6 
To assess the duration of anesthesia, the testing will be concluded when the study subject reported 
'pain' on two successive tests with 5 minutes in between. 
4.1.9 Cochet-Bonnet assessment 
For the assessment of corneal sensitivity the Luneau Cochet-Bonnet aesthesiometer (Western 
Ophthalmics Corporation©) will be used.  
The Cochet-Bonnet aesthesiometer contains a thin, retractable, nylon monofilament that extends up 
to 6 cm in length. Variable pressure can be applied to the cornea by adjusting the monofilament 
length. The monofilament length ranges from 6 to 0.5 cm. As the monofilament length is decreased 
the pressure increases from 11 mm/g to 200 mm/g.  
Only one assessment will be performed immediately after the last conjunctival anaesthesia 
assessment (either after 60 or if applicable after 80 seconds). 
4.1.10 Urine Pregnancy test 
Pregnancy test will be performed in females of childbearing potential at visit 1 and visit 2. 
A negative urine pregnancy test result is required at visit 1 and visit 2 for the patient to be involved 
in the study. 
 
4.2  Adverse events 
4.2.1 Adverse events recorded throughout the study 
A brief summary of AE definition, classification and management is reported below. 
 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 27/42 
4.2.2 Definitions 
 
 Adverse event (AE) 
Any untoward medical occurrence in a clinical trial subject administered a pharmaceutical 
product and which does not necessarily have a causal relationship with this treatment. 
 
 Adverse Drug Reaction (ADR) 
Any noxious and unintended response to a medicinal product (i.e. a causal relationship 
between a medicinal product and an AE is at least reasonably possible in the investigator's 
or sponsor's opinion, the relationship cannot be ruled out) resulting not only from the 
authorized use of a medicinal product at normal doses, but also from medication errors and 
uses outside the terms of the marketing authorization, including the misuse and abuse of the 
medicinal product. 
 
 Pre-treatment AE (PTAE) 
Any AE occurring before the first dose of a medicinal product and not worsening after the 
first dose. The following medical occurrences and clinical investigations are the only clinically 
significant events which, according to the investigator judgement, can be defined and 
recorded as PTAEs: 
• 
trauma (fractures, sprains, strains, falls, domestic accidents, car accidents, etc.) occurred 
after the signature of the informed consent and before the first medicinal product 
administration 
• 
new measurements (vital signs, ECG, laboratory parameters, etc.), performed after the 
signature of the informed consent and before the first medicinal product administration, 
which show a clinically significant worsening in comparison with a previous (baseline) 
measurement performed after the signature of the informed consent 
• 
any disease diagnosed after the anamnesis recorded at visit 1 and before the first medicinal 
product administration  
• 
physical and mental status changes (pre-syncope, anxiety, dizziness, fainting, etc.) 
occurred after the signature of the informed consent and before the first medicinal product 
administration 
 
 Treatment-emergent AE (TEAE) 
Any AE occurring or worsening after the first dose of a medicinal product 
 
 Serious Adverse Event (SAE) 
Any untoward medical occurrence that at any dose:  
• 
results in death 
• 
is life-threatening 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 28/42 
• 
requires inpatient hospitalization or prolongation of existing hospitalization 
• 
results in persistent or significant disability/incapacity 
• 
is a congenital anomaly/birth defect 
• 
is an important medical event that may jeopardize the subject’s health status or may require 
intervention to prevent one of the other outcomes listed in the definition above. Examples 
of such events are cancer, intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or 
development of drug dependency or drug abuse 
 
 Unexpected ADR:  
An ADR the nature or severity of which is not consistent with the Reference Safety 
Information (RSI) 
 
 Reference Safety Information (RSI):  
In order to assess whether an adverse reaction is expected, the Investigator’s Brochure (IB) 
for the test formulation will be used. 
 
 Suspected Unexpected Serious Adverse Reaction (SUSAR) 
An ADR that is both unexpected (not consistent with the RSI) and also meets the definition 
of a SAE. 
 
4.2.3 AEs monitoring window 
• 
Start of monitoring: from immediately after the signature of the informed consent 
• 
End of monitoring: last follow-up visit/Early Termination Visit (ETV)  
An AE occurring after the last follow-up visit/ETV and coming to knowledge of the investigator (e.g. 
by spontaneous reporting by study subjects) must be recorded only if it is an ADR, according to the 
investigator’s judgment. 
 
4.2.4 AEs recording 
All AEs derived by spontaneous, unsolicited reports of the subjects, by observation and by routine 
open questioning should be collected and reported. 
The following minimal information will be recorded for an AE in the source documents and later 
transcribed into the CRF: 
1. 
Adverse Event: progressive number of the adverse event or progressive number of follow-
up of the adverse event  
2. 
Description: verbatim description of the adverse event  
 
Start Date/Time: start date/time of the adverse event or  

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 29/42 
Follow-up Date/Time: follow-up date/time of the adverse event  
3. 
End Date/Time: end date/time of the adverse event  
4. 
Affected Body Area: anatomical location relevant for the event; in case of an 
ophthalmological AE, then it needs to be recorded whether or not it is the study eye 
5. 
Whether the adverse event start before or after the first intake of the study drug or whether 
the adverse event has worsened or not after the first intake of the study drug 
6. 
Last Study Drug Administration Date/Time Before Onset: if the adverse event started after 
the first administration of the study drug, the date/time of last administration of the study 
drug before the onset of the adverse event or 
Last Study Drug Administration Date/Time Before Worsening: In case of treatment 
emergent adverse event, the date/time of the last administration of the study drug(s) before 
the worsening of the adverse event.  
7. 
Investigator's opinion about the reasonable possibility of a causal relationship with the 
study drug.  
8. 
Investigator's opinion about other causal relationship (e.g. non study drug, concomitant 
therapy, study device, etc.).  
9. 
Severity: the severity or intensity of the event 
1 Mild  
2 Moderate 
3 Severe 
 
10. Pattern: Used to indicate the pattern of the event over time 
1 Single Event 
2 Continuous 
3 Intermittent 
11. Serious Adverse Event  
12. Action Taken with Study Drug: describes changes to the study drug as a result of the event. 
It is specifically for actions taken with the study drug 
1 Dose Not Changed 
2 Dose Increased 
3 Dose Reduced 
4 Drug Interrupted (i.e. temporary stop) 
5 Drug Withdrawn (i.e. definitive stop) 
6 Not Applicable (e.g. drug administration not started yet or completed) 
7 Unknown 
13. Concomitant Therapy: if a concomitant therapy is given, it must be reported in the specific 
CRF forms 
14. Study Discontinuation: if the adverse event causes the subject to be discontinued from the 
study 
15. Other Action Taken: other actions taken as a result of the event that are unrelated to dose 
adjustments of study drug 
16. Outcome: Outcome of the event 
1 Recovered/Resolved 
2 Recovered/Resolved with Sequelae 
3 Recovering/Resolving 
4 Not Recovered/Not Resolved 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 30/42 
5 Fatal 
6  Unknown 
 
4.2.5 SAEs reporting 
The pharmacovigilance will be under the control of the Sponsor, Sintetica SA.  
The investigator must report to the sponsor any SAE within 24 h of becoming aware of the event. 
The Investigator, within the same timeframe, should also inform the study monitor and the CRO. The 
investigator shall notify the competent Ethics Committee (EC) within 7 days of any SAE with lethal 
outcome occurred during a study, when required. If the Investigator is initially unable to obtain all the 
necessary details for completing the form, he/she should in any case transmit all the available 
information. The Investigator should provide an appropriate follow-up of SAEs to all concerned 
parties. 
Seriousness and causality must be assessed by the investigator. Expectedness is usually assessed 
by the sponsor. 
If the investigator is unable to assess the causality it is recommended to adopt a conservative 
approach and treat the event as a suspected adverse reaction until follow-up information is available. 
The sponsor may also make an assessment of causality, independent of that of the investigator. The 
most conservative approach should be taken when it comes to regulatory reporting. Under no 
circumstances should the sponsor downgrade the investigator's opinion or put the investigator under 
pressure to change his/her assessment. In case of disagreement, both the opinion of the investigator 
and the sponsor should be provided on the report. 
The sponsor will evaluate the SAE expectedness on the basis of the RSI. 
 
4.2.6  SUSARs management 
The clock for initial expedited reporting starts as soon as the information containing the minimum 
reporting criteria has been received by the sponsor (day 0).  
For fatal and life-threatening SUSARs the EC and Competent Authority (CA) should be informed as 
soon as possible and in any case within 7 days. 
If the initial report is incomplete, e.g. not all the information/assessments were available, a complete 
report should be sent within an additional 8 days. 
SUSARs which are not fatal and not life-threatening are to be reported within 15 days. 
The minimum information to be reported includes: 
• 
Valid EudraCT number (where applicable) 
• 
Sponsor study number 
• 
One identifiable coded subject 
• 
One identifiable reporter 
• 
One SUSAR 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 31/42 
• 
One suspect IMP (including active substance name, code) 
• 
A causality assessment (a reasonable possibility of a causal relationship with the study drug 
can be excluded only if there is information supporting this decision, otherwise it cannot be 
excluded). 
 
4.2.7  Other events qualified for expedited reporting 
Other safety issues also qualify for expedited reporting when they might materially alter the current 
benefit-risk assessment of a medicinal product or would be sufficient to consider changes in the 
medicinal product administration or in the overall conduct of the trial, for instance: 
• 
single case reports of an expected serious adverse reaction with an unexpected outcome 
(e.g.: a fatal outcome) 
• 
an increase in the rate of occurrence of an expected serious adverse reaction, which is 
judged to be clinically important. 
• 
post-study SUSARs that occur after the subject has completed a clinical trial and are 
reported to the investigator by the subject. 
• 
new events relating to the conduct of the trial or the development of the medicinal product 
likely to affect the safety of the subjects, such as: 
− a SAE which could be associated with the trial procedures and which could modify the 
conduct of the trial 
− a significant hazard to the subject population such as lack of efficacy of a medicinal 
product used for the treatment of a life-threatening disease 
− a major safety finding from a newly completed animal study (such as carcinogenicity) or 
from other clinical trials. 
 
4.2.8  SAEs: contacts 
The Pharmacovigilance can be contacted using the phone and fax numbers stated in this protocol.  
SAEs must be reported on SAE reporting forms and faxed/emailed within 24 H to sponsor - contact 
details below: 
Corporate Drug Safety Unit 
Fax: +41(0)91.646.85.61 - Phone: +41(0)91.640.42.50 
Email: corporate_drug_safety@sintetica.com 
 
4.3 
Data handling procedures 
Designated site staff must enter the information required by the protocol onto the CRFs. A subject 
ID list will be kept in the source data of the Department of Clinical Pharmacology. 
Data management will be performed by IDDI under the responsibility of the sponsor.  The sponsor 
will provide the investigator site with a web base electronic data capture (EDC) system that is fully 
validated and conforms to 21 CFR Part 11 requirements.  Investigator site staff will not be given 
access to EDC system until they have been trained on the EDC system. 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 32/42 
 
4.4 
Statistical methods 
All parameters measured will be evaluated and presented using descriptive statistics, i.e. arithmetic 
mean, SD, minimum, median and maximum values for quantitative variables, and absolute and 
relative (%) frequencies for qualitative variables. Results will be reported by treatment group. 
Confidence intervals will be reported, where appropriate. If not stated elsewhere, these intervals 
will be two sided in each case and provide 95% confidence.  
Not available data will be evaluated as “missing values”. A statistical analysis plan (SAP) will be 
provided before database closure. The statistical analysis will be performed using RStudio v. 
1.2.5033 and/or IBM SPSS Statistics v. 25 (or newer) for Windows. 
4.4.1 Determination of sample size 
Part I: 
The rationale for the sample size and the randomization scheme was based on similar studies 
investigating eye drops in healthy subjects in a dose-escalating manner. For example, in the 
Tanihara et al study (2013)7 there were 10 subjects per group (50 subjects in total), and the 
randomization scheme was 4:1. Considering the exploratory nature of part I of the study and the 
sample size used in similar studies, it deemed appropriate to use 12 subjects per group and 36 
subjects in total. No power calculations have been performed for this part of the study. 
 
Part II: 
60 healthy female or male subjects will be included in Part II: 40 subjects will be treated with 
chloroprocaine and 20 subjects will be treated with placebo. We chose the 2:1 allocation rate (with 
the experimental treatment having more patients than the vehicle arm) since the experimental 
treatment is a new product and we wanted to be able to estimate its success rate with more precision. 
Sample size per group was calculated for comparing two independent proportions (experimental and 
placebo success rate) with a two-sided alpha=0.05 and a power of 0.95. This is based on the 
assumption, that the experimental success rate is 80% and the vehicle success rate is 30%, taking 
a dropout rate of 20% into account. For sample size estimation, RStudio (Version 1.2.5001) was 
used implementing formulas described in Chow et al (2008).8 
 
4.4.2 Analysis sets 
The following analysis sets will be considered: 
Safety set:  
All patients enrolled in the study, for which there is evidence 
that they used study medication and for whom any follow-up 
information is available. 
Full Analysis Set (FAS): 
All patients enrolled in the study for which any follow-up efficacy 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 33/42 
information is available. 
Per Protocol Set (PPS): 
All patients of the FAS who did not show any major protocol 
violation. 
The exclusion of patients from the analysis sets will be discussed during a blind review meeting that 
will be held before database lock. 
The statistical analysis of the onset data and of efficacy will be performed on the basis of the FAS 
and the PPS.  The primary population for the assessment of efficacy will be the FAS, while the 
statistical analysis on the PPS population will be considered as sensitivity analysis. The analysis of 
safety will be performed on the basis of the safety set. Patients preventing primary endpoint 
assessment to be performed will be withdrawn from the efficacy analysis. Such patients' 
characteristics will be tabulated and compared with the characteristics of the rest of the patients to 
investigate potential between group differences. 
4.4.3 Handling of missing data 
Not available data will be evaluated as “missing values”.  All missing data will not be replaced. 
4.4.4 Statistical analysis plan 
Part I:  
In this part of the study, no formal statistical analysis (i.e. hypothesis testing) will take place. 
Safety will be assessed using the frequency of adverse events and results from the slit lamp 
evaluation. The safety board will decide whether the safety profile is acceptable to proceed in 
part II of the study.  
 
Part II: 
All parameters measured will be evaluated and presented using descriptive statistics, i.e. 
arithmetic mean, SD, minimum, median and maximum values for quantitative variables, and 
absolute and relative (%) frequencies for qualitative variables. In this part of the study, the list of 
quantitative variables includes time to anesthesia, duration of anesthesia, Cochet Bonnet 
assessment, blood pressure, heart rate, intraocular pressure, ocular symptoms, slit lamp 
examination and corneal fluorescein staining, while qualitative variables include the experience 
of full anesthesia of the ocular surface and the occurrence of adverse events. Moreover, results 
will be reported by treatment group. In terms of figures, quantitative variables will be presented 
by either histograms or box-plots, and qualitative variables will be presented by either bar-charts 
or pie-charts. Confidence intervals will be reported, where appropriate. If not stated elsewhere, 
these intervals will be two sided in each case and provide 95% confidence.  
The primary endpoint of the part II of the study is defined as the proportion of subjects gaining 
full anesthesia of the ocular surface 5 minutes after administration of the IMP for the 2 treatment 
arms (i.e. p1 for vehicle and p2 for Chloroprocaine arm). The null hypothesis of equal response 
rates between the 2 treatment arms (i.e. H0: p1=p2) at the α=0.05 level will be rejected if: 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 34/42 
ተተ
𝑝𝑝1
ෞ−𝑝𝑝2
ෞ
ට𝑝𝑝1
ෞ(1 −𝑝𝑝1
ෞ)
𝑛𝑛1
+ 𝑝𝑝2
ෞ(1 −𝑝𝑝2
ෞ)
𝑛𝑛2
ተተ> 𝑍𝑍α 2
ൗ 
In terms of statistical inference for the secondary endpoints, quantitative variables will be 
compared between the 2 groups using Mann-Whitney’s test, in which the null hypothesis is that 
for each quantitative variable tested, its median value does not differ significantly between the 2 
groups (i.e. H0: median1=median2). Qualitative variables will be compared using Pearson’s X2 
test, in which the null hypothesis for each pair of qualitative variables is that these two variables 
are not associated. To account for multiple comparisons, we will adjust the statistical significance 
level using Bonferroni corrections. 
In terms of adverse events, all AEs and SAEs will be reported in tabular form overall and 
separately for each treatment. Not available data will be evaluated as “missing values”. A 
statistical analysis plan (SAP) will be provided before database closure. A p-value<0.05 will be 
considered statistically significant. The statistical analysis will be performed using RStudio v. 
1.2.5033 and/or IBM SPSS Statistics v. 25 (or newer) for Windows. 
 
4.4.5 Safety and tolerability evaluation 
AEs 
Adverse events (AEs) are described analytically in 4.2 and will be coded by System Organ Class 
(SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA). 
AEs will be classified as pre-treatment AEs (PTAEs) and treatment-emergent AEs (TEAEs), 
according to the period of occurrence, as follows:  
• 
PTAEs: all AEs occurring before the first dose of IMP and not worsening after the first dose of 
IMP 
• 
TEAEs: all AEs occurring or worsening after the first dose of IMP 
Individual PTAEs and TEAEs will be listed in subject data listings. No summary table will be provided 
for PTAEs. TEAEs will be summarized by treatment and overall. The number and percentage of 
subjects with any TEAE and the number of TEAEs will be tabulated by SOC and PT, seriousness, 
relationship to treatment and severity.  
Physical examination 
Significant findings/illnesses, reported after the start of the study and that meet the definition of an 
AE (see section 4.2.1), will be recorded in the subject source documents. Date of the physical 
examination and overall investigator’s interpretation (as normal, abnormal not clinically significant 
[NCS] or abnormal clinically significant [CS]) will be reported in the CRF. 
Vital signs 
Values of vital signs will be listed and summarized by descriptive statistics.  

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 35/42 
5. Ethical and legal aspects 
The study will be performed in accordance with the guidelines of the Declaration of Helsinki (1964), 
including current revisions. The study will be also conducted in accordance with the protocol and 
ICH-GCP and the applicable regulatory requirement(s). 
5.1 
Informed consent of subjects 
In obtaining and documenting informed consent, the Investigator must comply with the applicable 
regulatory requirement(s) and adhere to the ICH guideline for GCP and the requirements in the 
Declaration of Helsinki. 
Prior to any trial-related activity, the Investigator must give the subject oral and written information 
about the trial expressed in the appropriate local language and form that the person giving consent 
can read and/ or understand. The measures taken to safeguard the subject´s privacy and the 
protection of personnel data should be described. This includes information on how the identity of 
the subject and any recorded data will be coded, stored and protected. Information should be given 
about the person(s) who will have access to the code list data, where the list will be kept and for how 
long and who will be responsible for keeping and destroying it.  
A voluntary, signed and dated Subject Information Sheet/Informed Consent Form (SIS/ICF) will be 
obtained from the subject prior to any trial-related activity. The subject will be given a copy of the 
signed SIS/ICF. 
5.2 
Approval of the study/Protocol Amendment/Study Termination 
5.2.1 
Approval of the study 
Before the start of the study, the study protocol will be submitted to the Ethics Committee (EC) of the 
Medical University of Vienna and the competent authorities (BASG). Without any approval, the study 
shall not begin. If any additional requirements are emposed by the EC or competent authorities, they 
shall be followed.  
5.2.2 
Protocol Amendment 
Full compliance with this protocol is expected.  
If any modifications become necessary or desirable, these will be documented in writing, major 
changes require the approval of all investigators, the sponsor, the ethics committee and the 
competent authorities. 
5.2.3 
Study Termination 
As required by the legislation the sponsor must submit to the IEC/IRB/Competent Authorities:  
  Information on suspected unexpected serious adverse reactions,  
  Periodic safety reports, when applicable,  
  Periodic reports on the progress of the study, when applicable,  

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 36/42 
  New information that may affect adversely the safety of the patients or the conduct of the trial  
  Serious breaches inherent to the study protocol, as per regulatory requirements.  
The study will be considered terminated at the date of the last visit of the last subject or upon 
completion of any follow-up procedure described in protocol.).  
Information about the end of the study will be transmitted to EC/CA according to local regulation. 
5.3 
Insurance 
All subjects participating in this clinical study will be insured in accordance with § 32 of the Austrian 
Medicines Act, 93. 
5.4 
Confidentiality 
All subject names will be kept confidential in the investigator's files. Subjects will be identified 
throughout documentation and evaluation by the number(s) assigned to them at the beginning of the 
study. The subjects will be told that all study findings will be stored and handled in strictest 
confidentiality. 
The investigator will maintain a personal patient identification list (patient numbers with the 
corresponding patient names) to enable records to be identified.  
Patients will be informed that representatives of the sponsor or the sponsor’s representative, 
IEC/IRB, or competent authorities may inspect their medical records to verify the information 
collected, and that all personal information made available for inspection will be handled in strictest 
confidence and in accordance with local data protection laws.  
Each participating site will maintain appropriate medical and research records for this trial in 
compliance with ICH E6(R2) GCP Sections 1.51, 1.52 and 4.9 and any other regulatory and 
institutional requirements for the protection of patient’s confidentiality.  
5.5  
Patients compensation 
Patient compensation is proposed due to the constraints required by the study protocol and will be 
submitted to the IRB/IEC for approval.  
5.6  
Study Duration 
The study will be closed when all patients have completed the last study visit.  
 
6. Data quality assurance 
6.1 
Monitoring 
Monitoring visits will be performed by a study monitor designated by the sponsor. The study monitor 
will be dully trained to the study and will be responsible for ensuring and verifying that each study 
site conducts the study according to the protocol, standard operating procedures, other written 
instructions/agreements, ICH-GCP, and applicable regulatory guidelines/requirements. The 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 37/42 
investigator will permit the study monitor to visit the study site at appropriate intervals to observe the 
progress of the study, review study records/documentation, and ensure that informed consent has 
been obtained. 
6.2 
Documentation of study findings 
All findings collected during the study will be entered in the electronic CRFs provided by the CRO 
and data management activities will be performed by the CRO designated by the sponsor. 
eCRFs will be completed based on the source data within 3 working days of the patient visit.  
The medical records upon which the CRF is based will be kept for at least 15 years. 
6.3 
Auditing and inspections 
The investigator will permit study-related monitoring, audits, review of the Ethics Committee, and 
regulatory inspection(s) to evaluate study conduct and compliance with the protocol, standard 
operating procedures, other written instructions/agreements, ICH GCP, and applicable regulatory 
guidelines/requirements. For this purpose, the investigator will provide direct access to source data 
documents. This will be carried out giving due consideration to data protection and medical 
confidentiality.  
 
7. Publication policy  
The sponsor agrees that the study results (including negative and inconclusive as well as positive 
results) can be made publicly available by the investigator publishing in peer reviewed journals, 
presenting results at scientific congresses and posting information and results on internet-based 
public registers and databases. 
Study results will be communicated in full to the competent Health Authorities by the submission of 
a complete clinical study report. The sponsor will be in charge of the Clinical Study Report writing 
As the sponsor agrees that the study results can be published by the investigator(s), the investigator 
agrees to submit any manuscript (abstract, publication, paper, etc.) to the sponsor before any public 
disclosure. 
This will be done in order to ensure that clinical study results are reported in an objective, accurate 
and balanced manner. The sponsor reviews the proposed manuscripts, before submission, within a 
reasonable period of time (30-90 days in relation with the complexity of the work). 
The investigator(s) will also be provided by the sponsor with the clinical study report and the results 
of any additional analysis, tables, figures, etc. undertaken for the purposes of the article, in order to 
take responsibility for the content of the publication(s). 
On an exceptional basis, the sponsor may temporarily delay registration of certain data elements 
(e.g. compound, name, outcome, measures, etc.) to seek necessary intellectual property protection. 
This is because early disclosure of such data could, in some circumstances, prevent or negatively 
impact patentability. 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 38/42 
8. References 
 
 
1. 
Pham DT, Castello R. [Topical anaesthesia in cataract surgery]. Klin Monbl Augenheilkd 
2010;227:605-610. 
2. 
Goldblum E, Atchabahian A. The use of 2-chloroprocaine for spinal anaesthesia. Acta 
Anaesthesiol Scand 2013;57:545-552. 
3. 
Moisseiev E, Loberman D, Zunz E, Kesler A, Loewenstein A, Mandelblum J. Pupil dilation using 
drops vs gel: a comparative study. Eye (Lond) 2015;29:815-819. 
4. 
Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. 
CLAO J 1995;21:221-232. 
5. 
Gellrich M-M. The fundus slit lamp. SpringerPlus 2015;4:56-56. 
6. 
Busbee BG, Alam A, Reichel E. Lidocaine hydrochloride gel for ocular anesthesia: results of a 
prospective, randomized study. Ophthalmic Surg Lasers Imaging 2008;39:386-390. 
7. 
Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H and Araie M for the K-115 Clinical   
Study Group. Phase 1 clinical trials of a selective Rho kinase inhibitor. JAMA Ophthalmol 2013; 
131(10):1288-95. 
8. 
Chow S-C, Shao J, Wang H. Sample size calculations in clinical research: Chapman and 
Hall/CRC; 2008. 
 
 
 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 39/42 
9. Appendix: Schedule of assessments 
 

Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 40/42 
 
Schedule of assessments: Part I: 
 
Visit 1 
(Day -30 to -7) 
Visit 2 
(Day 1) 
Visit 3 
(phone) 
(Day 2) 
Visit 4 
(Day 8 ± 1) 
Visit 5 
(phone) 
(Day 29 ± 3) 
Informed consent 
X 
 
 
 
 
Urine Pregnancy test 
X 
X 
 
 
 
Demography 
X 
 
 
 
 
Ocular medical and surgical history 
X 
 
 
 
 
Systemic medical and surgical history 
X 
 
 
 
 
Ocular and systemic concomitant medication 
X 
X 
X 
X 
X 
Check of inclusion/exclusion criteria 
X 
X 
 
 
 
Height and Weight 
X 
 
 
 
 
Blood pressure and heart rate 
X 
X1) 
 
X 
 
Ocular symptoms 
X 
X1) 
 
X 
 
Best corrected visual acuity (ETDRS) 
X 
 
 
X 
 
Slit lamp examination 
X 
X1) 
 
X 
 
Corneal fluorescein staining 
X 
 
 
X 
 
Intraocular pressure 
X 
 
 
X 
 
Funduscopy 
X 
 
 
X 
 
Assessment of Adverse Events 
 
X2) 
X 
X 
X 
Randomization 
 
X 
 
 
 
Instillation of the IMP in the right eye 
 
X 
 
 
 
1) Before IMP instillation and at the end of the study day (at least 60 minutes ±10 minutes after instillation) 
2) Throughout the study day 
 
 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 41/42 
Schedule of assessments: Part II: 
 
Visit 1 
(Day -30 to -7) 
Visit 2 
(Day 1) 
Visit 3 
(phone) 
(Day 2) 
Visit 4 
(Day 8 ± 1) 
Visit 5 
(phone) 
(Day 29 ± 3) 
Informed consent 
X 
 
 
 
 
Urine Pregnancy test 
X 
X 
 
 
 
Demography 
X 
 
 
 
 
Ocular medical and surgical history 
X 
 
 
 
 
Systemic medical and surgical history 
X 
 
 
 
 
Ocular and systemic concomitant medication 
X 
X 
X 
X 
X 
Check of inclusion/exclusion criteria 
X 
X 
 
 
 
Height and Weight 
X 
 
 
 
 
Blood pressure and heart rate 
X 
X1) 
 
X 
 
Ocular symptoms 
X 
X1) 
 
X 
 
Best corrected visual acuity (ETDRS) 
X 
 
 
X 
 
Slit lamp examination 
X 
X1) 
 
X 
 
Corneal fluorescein staining 
X 
 
 
X 
 
Intraocular pressure 
X 
 
 
X 
 
Funduscopy 
X 
 
 
X 
 
Assessment of Adverse Events 
 
X3) 
X 
X 
X 
Randomization 
 
X 
 
 
 
Instillation of the IMP in the right eye 
 
X 
 
 
 
Assessment of conjunctival anaesthesia4) 
 
X2) 
 
 
 
Cochet Bonnet assessment4) 
 
X5) 
 
 
 

 
Protocol No CHL.3-02-2019 
Efficacy Chloroprocaine gel eye drops Version No 2.0 – 04 May 2020 
page 42/42 
1) Before IMP instillation and at the end of the study day 
2) Subjects will be tested and then questioned about pain at 20 seconds, 40 seconds, and 1 minute. The resting (pinching and cornea touching) intervals will 
be extended to every 5 minutes once a subject reports no pain on two successive tests.  
These subjects will be considered to have achieved the primary endpoint of anesthesia by 5 minutes.  
Alternatively, if the subject experiences pain at 20, 40, and 60 seconds, pinching will be suspended to the 5-minute time point. If the subject experiences 
pain at this testing interval (5 minutes), no more testing will be performed and the subject will be considered not to have gained anesthesia.  
3) Throughout the study day 
4)  Examinations will only be performed in the right eye 
5)  Cochet Bonnet assessment will be performed starting from 60 (or 80) seconds after instillation, immediately after assessment time points for conjunctival 
anesthesia